Haroun Riham Abdel-Hamid, Eweida Soad M, Elsaid Dina Samir, Al-Dosoky Mona A, Elbedewy Tamer A, Keshk Rabab Alaa-Eldin, Gamal-Eldin Sally M
Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.
Department of Biochemistry, National Research Centre, Dokki, Giza, Egypt.
Biochem Genet. 2025 Apr 23. doi: 10.1007/s10528-025-11094-3.
Multiple myeloma (MM) frequently causes renal impairment (RI), and clinical therapy becomes more challenging if renal function deteriorates or renal failure results. Therefore, in order to evaluate their prognostic potential in predicting renal impairment risk in MM patients, we investigated the expression levels of miR- 17 - 5p and miR- 125a- 5p as well as STAT3 and CD69 proteins as probable shared target genes in MM adult patients with and without RI. This study included 60 controls and 120 MM patients. By using RT-qPCR, the expression levels of miR- 17 - 5p and miR- 125a- 5p in the sera of MM patients and controls were evaluated. Also, the expression levels of CD69 and STAT- 3 were examined using ELISA and flowcytometry techniques, respectively. When MM patients were compared to controls and MM patients with RI to MM patients without RI, the expression levels of miR- 17 - 5p and miR- 125a- 5p were reduced, but CD69 and STAT- 3 were elevated. Results obtained from ROC curve showed that they were good prognostic biomarkers could predict renal impairment in MM patients, with AUC 0.754, 0.936, 1 & 0.991; respectively for miR- 17 - 5p, miR- 125a- 5p, STAT- 3 and CD69, 60%, 93.3%, 100% & 96.7% sensitivity and 73.3%, 86.7%, 100% & 90% specificity; respectively for miR- 17 - 5p, miR- 125a- 5p, STAT- 3 and CD69. While for Kaplan-Meier survival, our results indicated that patients with lower expression levels of miR- 17 - 5p and miR- 125a- 5p, but higher STAT- 3 and CD69 concentration, had a poorer prognosis and possessing a shorter OS. The integrated approach reveals miR- 17 - 5p, miR- 125a- 5p, CD69, and STAT- 3 as reliable prognostic biomarkers for predicting renal impairment in MM patients.
多发性骨髓瘤（MM）常导致肾功能损害（RI），如果肾功能恶化或出现肾衰竭，临床治疗将更具挑战性。因此，为了评估miR-17-5p和miR-125a-5p以及STAT3和CD69蛋白作为MM成年患者有无RI的可能共同靶基因在预测肾功能损害风险中的预后潜力，我们进行了研究。本研究纳入60名对照者和120名MM患者。通过逆转录定量聚合酶链反应（RT-qPCR）评估MM患者和对照者血清中miR-17-5p和miR-125a-5p的表达水平。此外，分别使用酶联免疫吸附测定（ELISA）和流式细胞术检测CD69和STAT-3的表达水平。将MM患者与对照者以及有RI的MM患者与无RI的MM患者进行比较时，miR-17-5p和miR-125a-5p的表达水平降低，但CD69和STAT-3升高。从受试者工作特征（ROC）曲线获得的结果表明，它们是预测MM患者肾功能损害的良好预后生物标志物，miR-17-5p、miR-125a-5p、STAT-3和CD69的曲线下面积（AUC）分别为0.754、0.936、1和0.991；敏感性分别为60%、93.3%、100%和96.7%；特异性分别为73.3%、86.7%、100%和90%。而对于Kaplan-Meier生存分析，我们的结果表明，miR-17-5p和miR-125a-5p表达水平较低但STAT-3和CD69浓度较高的患者预后较差，总生存期较短。综合分析表明，miR-17-5p、miR-125a-5p、CD69和STAT-3是预测MM患者肾功能损害的可靠预后生物标志物。
